We came across a bullish thesis on Recursion Pharmaceuticals, Inc. on r/stocks by Antique-Reference585. In this article, we ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best debt-free penny stocks to buy right now. On December 17, ...

We recently compiled a list of the Last Week’s Top 10 Stocks Post Double-Digit Gains. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against ...

Bayer and digital biology company Recursion Inc. entered into a strategic collaboration agreement to leverage Recursion’s purpose-built, artificial intelligence-guided drug discovery platform and ...

Recursion Pharmaceuticals' stock experienced a 10.06% surge on Monday, indicating strong investor confidence in the company's innovations. The completion of BioHive-2 marks a pivotal moment for ...

The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 16.03 / share. This is an increase of 8.91% from the prior estimate of 14.72 dated July 5, 2023.

We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was one of the top performers on Wednesday. Recursion extended its winning streak ...

Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...

Fintel reports that on May 9, 2023, Keybanc maintained coverage of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) with a Overweight recommendation. As of April 24, 2023, the average one-year price ...

Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, delighted to be joining you on our L(earnings) today. And I'm joined by our Chief R&D and Commercial Officer, Najat Khan and ...

Recursion Pharmaceuticals, Inc., the Salt Lake City based AI-driven drug developer, has agreed to combine businesses with Exscientia plc, a former rival, based in the UK. Neither company has delivered ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12 ...